Yes, Osphena Treats Painful Intercourse
Osphena (ospemifene) is FDA-approved specifically for treating moderate to severe dyspareunia—painful intercourse due to menopausal vaginal atrophy changes in and around the vagina.[1][2] It works as a selective estrogen receptor modulator (SERM), mimicking estrogen's effects locally in vaginal tissue to restore moisture, thickness, and elasticity, which reduces pain during sex.[3]
How Osphena Differs from Other Vaginal Atrophy Treatments
Unlike topical estrogen creams or rings, Osphena is an oral tablet taken once daily, avoiding direct vaginal application.[1] Clinical trials showed it reduced dyspareunia scores by 0.7-1.0 points on a 4-point scale versus placebo after 12 weeks, with superficial cell counts increasing over 20%.[4] It's not for hot flashes or osteoporosis, unlike broader hormone therapies.
Who Qualifies for Osphena
Prescribed for postmenopausal women with vaginal dryness and pain during sex not improved by lubricants or moisturizers.[2] Not for premenopausal women, those with breast cancer history, or active thromboembolic events due to clotting risks.[1]
Common Side Effects and Risks Patients Report
Hot flashes (21%), vaginal discharge (10%), muscle spasms (7%), and excess sweating occur most often.[1] Black box warning for stroke, deep vein thrombosis, and pulmonary embolism risk, similar to estrogen therapies—avoid in women over 65 or with clotting history.[2][3] Vaginal bleeding warrants immediate doctor visit.
How Long Until Osphena Starts Working
Pain relief often begins within 4 weeks, with full effects by 12 weeks based on phase 3 trials.[4] Daily 60 mg dose; effects reverse after stopping.
Osphena vs. Competitors like Intrarosa or Estrogen Creams
| Treatment | Form | Key Mechanism | Dyspareunia Approval | Clotting Risk |
|-----------|------|---------------|----------------------|--------------|
| Osphena | Oral tablet | SERM (estrogen-like in vagina) | Yes | Yes (black box) |
| Intrarosa (prasterone) | Vaginal insert | Local DHEA to estrogen/androgen | Yes | No |
| Estrace/Vagifem (estradiol) | Cream/insert | Local/systemic estrogen | Yes | Low local, higher systemic |
| Laser therapies (e.g., MonaLisa) | In-office procedure | Tissue regeneration | Off-label for atrophy | Minimal |
Osphena suits those preferring pills; Intrarosa avoids hormones entirely.[5]
Cost and Access Issues
Costs $200-500 monthly without insurance; generics unavailable until patent expiry around 2027-2029 per DrugPatentWatch.[6] Patient assistance programs from Duchesnay cover copays for eligible uninsured.
Sources
[1] Osphena Prescribing Information (FDA)
[2] FDA Approval Summary
[3] Osphena Mechanism (Medscape)
[4] Phase 3 Trial Data (NEJM)
[5] Comparative Review (JAMA)
[6] DrugPatentWatch: Osphena Patents